TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Management of Childhood Diabetes Study
Brief Summary: This is a multi-center, randomized controlled trial to test whether a clinic-integrated, low intensity, multi-component behavioral intervention is effective in preventing the deterioration in glycemic control, treatment adherence, and quality of life that commonly occur during late childhood and early adolescence in youth with type 1 diabetes. The study will also examine mechanisms and processes that influence the effectiveness of family management of diabetes during this developmental period.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: FL3X: Flexible Lifestyle Empowering Change | Intervention Type: BEHAVIORAL; Name: FL3X: Flexible Lifestyle Empowering Change; Assigned to Arm(s): Intervention
B: Arm Label: Active Comparator: Internet Resources Comparison (IRC); Type: EXPERIMENTAL; Interventions: Behavioral: Internet Resources Comparison (IRC) | Arm Label: I-InTERACT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT) | Arm Label: I-InTERACT Express; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express) | Intervention Type: BEHAVIORAL; Name: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT); Assigned to Arm(s): I-InTERACT | Intervention Type: BEHAVIORAL; Name: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express); Assigned to Arm(s): I-InTERACT Express | Intervention Type: BEHAVIORAL; Name: Internet Resources Comparison (IRC); Assigned to Arm(s): Active Comparator: Internet Resources Comparison (IRC)
C: Arm Label: family diabetes management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: family diabetes management intervention | Intervention Type: BEHAVIORAL; Name: family diabetes management intervention; Assigned to Arm(s): family diabetes management intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Asthma Program | Intervention Type: BEHAVIORAL; Name: Telephone Asthma Program; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Management of Childhood Diabetes Study
Brief Summary: This is a multi-center, randomized controlled trial to test whether a clinic-integrated, low intensity, multi-component behavioral intervention is effective in preventing the deterioration in glycemic control, treatment adherence, and quality of life that commonly occur during late childhood and early adolescence in youth with type 1 diabetes. The study will also examine mechanisms and processes that influence the effectiveness of family management of diabetes during this developmental period.


Options:
A: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
B: Intervention Type: BEHAVIORAL; Name: Problem-Solving Skills Training; Assigned to Arm(s): N/A
C: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)
D: Arm Label: family diabetes management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: family diabetes management intervention | Intervention Type: BEHAVIORAL; Name: family diabetes management intervention; Assigned to Arm(s): family diabetes management intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection
Brief Summary: The investigators will test the hypotheses that mild hypercapnia and supplemental oxygen reduce wound infection risk in patients undergoing colon resection. The investigators will simultaneously test the hypothesis that low-dose dexamethasone (a common treatment for postoperative nausea and vomiting) does not increase infection risk.


Options:
A: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Zofran; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Dexamethasone, Placebo
C: Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Gabapentin, Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine, Drug: Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Morphine, Multimodal
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic NaCl | Arm Label: dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone phosphate | Intervention Type: DRUG; Name: dexamethasone phosphate; Assigned to Arm(s): dexamethasone | Intervention Type: DRUG; Name: Isotonic NaCl; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection
Brief Summary: The investigators will test the hypotheses that mild hypercapnia and supplemental oxygen reduce wound infection risk in patients undergoing colon resection. The investigators will simultaneously test the hypothesis that low-dose dexamethasone (a common treatment for postoperative nausea and vomiting) does not increase infection risk.


Options:
A: Arm Label: high VT group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low tidal volume; Type: EXPERIMENTAL; Interventions: Procedure: Low tidal volume, Other: low tidal volume | Intervention Type: PROCEDURE; Name: Low tidal volume; Assigned to Arm(s): Low tidal volume | Intervention Type: PROCEDURE; Name: Low tidal volume; Assigned to Arm(s): Low tidal volume | Intervention Type: OTHER; Name: low tidal volume; Assigned to Arm(s): Low tidal volume
B: Arm Label: change respiratory parameters, volume expanding; Type: EXPERIMENTAL; Interventions: Other: 300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation | Intervention Type: OTHER; Name: 300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation; Assigned to Arm(s): change respiratory parameters, volume expanding
C: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: conventional ventilation, protective ventilation; Type: OTHER; Interventions: Procedure: change ventilation | Intervention Type: PROCEDURE; Name: change ventilation; Assigned to Arm(s): conventional ventilation, protective ventilation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection
Brief Summary: The investigators will test the hypotheses that mild hypercapnia and supplemental oxygen reduce wound infection risk in patients undergoing colon resection. The investigators will simultaneously test the hypothesis that low-dose dexamethasone (a common treatment for postoperative nausea and vomiting) does not increase infection risk.


Options:
A: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Zofran; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Dexamethasone, Placebo
C: Arm Label: A, 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A, 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethason Helvepharm ® | Intervention Type: DRUG; Name: Dexamethason Helvepharm ®; Assigned to Arm(s): A, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A, 1
D: Arm Label: dexamethasone; Type: N/A; Interventions: N/A | Arm Label: placebo; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection
Brief Summary: The investigators will test the hypotheses that mild hypercapnia and supplemental oxygen reduce wound infection risk in patients undergoing colon resection. The investigators will simultaneously test the hypothesis that low-dose dexamethasone (a common treatment for postoperative nausea and vomiting) does not increase infection risk.


Options:
A: Arm Label: 80% oxygen group; Type: N/A; Interventions: Drug: Oxygen | Arm Label: 30% oxygen group; Type: N/A; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): 30% oxygen group, 80% oxygen group
B: Arm Label: 80% perioperative oxygen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Perioperative supplemental oxygen | Arm Label: 30% perioperative oxygen; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Standard oxygen | Intervention Type: PROCEDURE; Name: Perioperative supplemental oxygen; Assigned to Arm(s): 80% perioperative oxygen | Intervention Type: PROCEDURE; Name: Standard oxygen; Assigned to Arm(s): 30% perioperative oxygen
C: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Nitrous Oxide; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Telithromycin 800 mg (Once Daily for 10 Days) as a Supplement to the Standard of Care for Patients With Acute Exacerbations of Asthma
Brief Summary: Primary Objective:

* The primary objective is to evaluate the clinical efficacy of telithromycin versus placebo as a supplement to the usual standard of care during an acute exacerbation of asthma. Efficacy will be assessed by:

  * Changes in the diary card summary symptom score assessed daily for 6 weeks, and
  * Changes in the domiciliary morning Peak Expiratory Flow Rate (PEFR) following oral telithromycin treatment

Secondary Objectives:

The secondary objectives of the study are:

* To evaluate the microbial activity of telithromycin during an exacerbation of asthma by:

  * Assessment of the patient's clinical improvement relative to initial C. pneumoniae or M. pneumoniae status, and
  * Analysis of the quantitative changes from baseline in C. pneumonia or M. pneumoniae by culture and quantitative Polymerase Chain Reaction (PCR).
* To evaluate the safety of 10 days of oral telithromycin as a supplement to the standard of care for patients with acute exacerbations of asthma
* To assess additional efficacy endpoints and health outcome evaluations following 10 days of treatment with either oral telithromycin or placebo, with either treatment used as a supplement to the standard of care for patients with acute exacerbations of asthma:

  * Changes and daily variability in the PEFR during the 6 weeks of study treatment,
  * Health status at follow-up (6 weeks)
  * Pulmonary function tests:

    * Forced Expiratory Volume in 1 second (FEV1)
    * Forced Vital Capacity (FVC)
    * Forced Expiratory Flow Rate (FEF25-75%)
  * Need for additional medications (e.g., inhaled corticosteroids, oral corticosteroids, bronchodilator use),
  * Time to next acute exacerbation of asthma.


Options:
A: Arm Label: Azithromycin (Zithromax); Type: EXPERIMENTAL; Interventions: Drug: Zithromax | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zithromax; Assigned to Arm(s): Azithromycin (Zithromax) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Telithromycin; Assigned to Arm(s): N/A
C: Arm Label: Antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo mixture | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Antibiotics | Intervention Type: OTHER; Name: Placebo mixture; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progression Free Survival in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Brief Summary: * 1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced SCCHN.
* 2.The main secondary endpoint is progression free survival (PFS). The other secondary endpoints are to evaluate and compare improvement of local symptoms; time-to-treatment failure; quality of life; clinical complete response rate (CR and CR/PR); toxicity and to evaluate the relationship of tumor markers and response to therapy.


Options:
A: Intervention Type: DRUG; Name: XRP6976 (Docetaxel/Taxotere); Assigned to Arm(s): N/A
B: Arm Label: Cetuximab Plus Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum (Cisplatin or Carboplatin) + 5-FU | Intervention Type: DRUG; Name: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU); Assigned to Arm(s): Cetuximab Plus Chemotherapy | Intervention Type: DRUG; Name: Platinum (Cisplatin or Carboplatin) + 5-FU; Assigned to Arm(s): Chemotherapy alone
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I
D: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progression Free Survival in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Brief Summary: * 1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced SCCHN.
* 2.The main secondary endpoint is progression free survival (PFS). The other secondary endpoints are to evaluate and compare improvement of local symptoms; time-to-treatment failure; quality of life; clinical complete response rate (CR and CR/PR); toxicity and to evaluate the relationship of tumor markers and response to therapy.


Options:
A: Arm Label: RT+CDDP/5-FU; Type: ACTIVE_COMPARATOR; Interventions: Drug: RT+CDDP/5-FU | Arm Label: RT+CETUXIMAB; Type: EXPERIMENTAL; Interventions: Drug: RT+CETUXIMAB | Arm Label: INDUCTION CTx(TPF)+(RT+CDDP/5-FU); Type: ACTIVE_COMPARATOR; Interventions: Drug: INDUCTION CTx(TPF)+(RT+CDDP/5-FU) | Arm Label: INDUCTION CTx(TPF)+(RT+CETUXIMAB); Type: EXPERIMENTAL; Interventions: Drug: INDUCTION CTx(TPF)+(RT+CETUXIMAB) | Intervention Type: DRUG; Name: RT+CDDP/5-FU; Assigned to Arm(s): RT+CDDP/5-FU | Intervention Type: DRUG; Name: RT+CETUXIMAB; Assigned to Arm(s): RT+CETUXIMAB | Intervention Type: DRUG; Name: INDUCTION CTx(TPF)+(RT+CDDP/5-FU); Assigned to Arm(s): INDUCTION CTx(TPF)+(RT+CDDP/5-FU) | Intervention Type: DRUG; Name: INDUCTION CTx(TPF)+(RT+CETUXIMAB); Assigned to Arm(s): INDUCTION CTx(TPF)+(RT+CETUXIMAB)
B: Arm Label: Radiotherapy plus or minus Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Arm Label: Transoral Robotic Surgery + Neck Dissection; Type: EXPERIMENTAL; Interventions: Procedure: Transoral Robotic Surgery + Neck Dissection | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy plus or minus Chemotherapy | Intervention Type: PROCEDURE; Name: Transoral Robotic Surgery + Neck Dissection; Assigned to Arm(s): Transoral Robotic Surgery + Neck Dissection
C: Intervention Type: DRUG; Name: XRP6976 (Docetaxel/Taxotere); Assigned to Arm(s): N/A
D: Arm Label: Induction chemotherapy + concurrent chemoradiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Arm Label: Concurrent radiochemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Intervention Type: PROCEDURE; Name: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy; Assigned to Arm(s): Concurrent radiochemotherapy alone, Induction chemotherapy + concurrent chemoradiotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Lifestyle Intervention Program on Parameters of the Metabolic Syndrome Among Non-Diabetic Obese Arab Women
Brief Summary: The study protocol aims to test the hypothesis that a lifestyle intervention program aimed to increase leisure-time physical activity and reduce body weight will improve the parameters of the metabolic syndrome and quality of life among obese, non-diabetic Arab women


Options:
A: Arm Label: Moderate lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Moderate Lifestyle Intervention | Arm Label: Intensive lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: Intensive lifestyle intervention | Intervention Type: OTHER; Name: Moderate Lifestyle Intervention; Assigned to Arm(s): Moderate lifestyle intervention | Intervention Type: OTHER; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention
B: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
C: Arm Label: Standard Behavioral Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Treatment | Arm Label: SBT+LOV Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Treatment, Behavioral: SBT+LOV | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Treatment; Assigned to Arm(s): SBT+LOV Group, Standard Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: SBT+LOV; Assigned to Arm(s): SBT+LOV Group
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program (SM) | Arm Label: Care Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Care management program (CM) | Intervention Type: BEHAVIORAL; Name: Self-management program (SM); Assigned to Arm(s): Self-Management Program | Intervention Type: BEHAVIORAL; Name: Care management program (CM); Assigned to Arm(s): Care Management Program

Answer: A